Business Wire

KAYTUS Unveils Upgraded MotusAI to Accelerate LLM Deployment

12.6.2025 13:11:00 CEST | Business Wire | Press Release

Share

KAYTUS, a leading provider of end-to-end AI and liquid cooling solutions, today announced the release of the latest version of its MotusAI AI DevOps Platform at ISC High Performance 2025. The upgraded MotusAI platform delivers significant enhancements in large model inference performance and offers broad compatibility with multiple open-source tools covering the full lifecycle of large models. Engineered for unified and dynamic resource scheduling, it dramatically improves resource utilization and operational efficiency in large-scale AI model development and deployment. This latest release of MotusAI is set to further accelerate AI adoption and fuel business innovation across key sectors such as education, finance, energy, automotive, and manufacturing.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612546292/en/

MotusAI Dashboard

As large AI models become increasingly embedded in real-world applications, enterprises are deploying them at scale, to generate tangible value across a wide range of sectors. Yet, many organizations continue to face critical challenges in AI adoption, including prolonged deployment cycles, stringent stability requirements, fragmented open-source tool management, and low compute resource utilization. To address these pain points, KAYTUS has introduced the latest version of its MotusAI AI DevOps Platform, purpose-built to streamline AI deployment, enhance system stability, and optimize AI infrastructure efficiency for large-scale model operations.

Enhanced Inference Performance to Ensure Service Quality

Deploying AI inference services is a complex undertaking that involves service deployment, management, and continuous health monitoring. These tasks require stringent standards in model and service governance, performance tuning via acceleration frameworks, and long-term service stability, all of which typically demand substantial investments in manpower, time, and technical expertise.

The upgraded MotusAI delivers robust large-model deployment capabilities that bring visibility and performance into perfect alignment. By integrating optimized frameworks such as SGLang and vLLM, MotusAI ensures high-performance, distributed inference services that enterprises can deploy quickly and with confidence. Designed to support large-parameter models, MotusAI leverages intelligent resource and network affinity scheduling to accelerate time-to-launch while maximizing hardware utilization. Its built-in monitoring capabilities span the full stack—from hardware and platforms to pods and services—offering automated fault diagnosis and rapid service recovery. MotusAI also supports dynamic scaling of inference workloads based on real-time usage and resource monitoring, delivering enhanced service stability.

Comprehensive Tool Support to Accelerate AI Adoption

As AI model technologies evolve rapidly, the supporting ecosystem of development tools continues to grow in complexity. Developers require a streamlined, universal platform to efficiently select, deploy, and operate these tools.

The upgraded MotusAI provides extensive support for a wide range of leading open-source tools, enabling enterprise users to configure and manage their model development environments on demand. With built-in tools such as LabelStudio, MotusAI accelerates data annotation and synchronization across diverse categories, improving data processing efficiency and expediting model development cycles. MotusAI also offers an integrated toolchain for the entire AI model lifecycle. This includes LabelStudio and OpenRefine for data annotation and governance, LLaMA-Factory for fine-tuning large models, Dify and Confluence for large model application development, and Stable Diffusion for text-to-image generation. Together, these tools empower users to adopt large models quickly and boost development productivity at scale.

Hybrid Training-Inference Scheduling on the Same Node to Maximize Resource Efficiency

Efficient utilization of computing resources remains a critical priority for AI startups and small to mid-sized enterprises in the early stages of AI adoption. Traditional AI clusters typically allocate compute nodes separately for training and inference tasks, limiting the flexibility and efficiency of resource scheduling across the two types of workloads.

The upgraded MotusAI overcomes traditional limitations by enabling hybrid scheduling of training and inference workloads on a single node, allowing for seamless integration and dynamic orchestration of diverse task types. Equipped with advanced GPU scheduling capabilities, MotusAI supports on-demand resource allocation, empowering users to efficiently manage GPU resources based on workload requirements. MotusAI also features multi-dimensional GPU scheduling, including fine-grained partitioning and support for Multi-Instance GPU (MIG), addressing a wide range of use cases across model development, debugging, and inference.

MotusAI’s enhanced scheduler significantly outperforms community-based versions, delivering a 5× improvement in task throughput and 5× reduction in latency for large-scale POD deployments. It enables rapid startup and environment readiness for hundreds of PODs while supporting dynamic workload scaling and tidal scheduling for both training and inference. These capabilities empower seamless task orchestration across a wide range of real-world AI scenarios.

About KAYTUS

KAYTUS is a leading provider of end-to-end AI and liquid cooling solutions, delivering a diverse range of innovative, open, and eco-friendly products for cloud, AI, edge computing, and other emerging applications. With a customer-centric approach, KAYTUS is agile and responsive to user needs through its adaptable business model. Discover more at KAYTUS.com and follow us on LinkedIn and X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250612546292/en/

Contacts

Media Contacts
media@kaytus.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye